AIM ImmunoTech Inc is trading at $0.43 (-84.27%) after regaining NYSE American compliance with stockholders’ equity requirements.
- The exchange removed the “below compliance” indicator after the company resolved its deficiency, marking a significant regulatory milestone.
- The company also disclosed new share issuance and private placement financing, which likely impacts the stock as traders monitor dilution and balance-sheet repair.
- The announcement is the primary driver of the price action, occurring while broader U.S. equity markets are in a risk-on state.